trial

Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant

NCTId NCT04418466
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 34 (actual)
Sponsored by Delpor, Inc.
Primary completion 2023-02-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
34 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Sequential
Masking
None
Start
2021-04-01
Primary completion
2023-02-10
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
Risperidone

Sponsors

Delpor, Inc.Lead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Sites

2 total
Long Beach, United StatesMiami Lakes, United States

Linked catalysts

1
Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to — primary completion2023-02-10

Facts & assertions

4 sourced
Enrollment
34
Phase
PHASE1,PHASE2
Primary Completion Date
2023-02-10
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
lead_sponsor
Delpor, Inc.
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication